182 related articles for article (PubMed ID: 3935046)
1. In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.
Eliopoulos GM; Moellering AE; Reiszner E; Moellering RC
Antimicrob Agents Chemother; 1985 Oct; 28(4):514-20. PubMed ID: 3935046
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
Stamm JM; Hanson CW; Chu DT; Bailer R; Vojtko C; Fernandes PB
Antimicrob Agents Chemother; 1986 Feb; 29(2):193-200. PubMed ID: 3087274
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of A-56619 and A56620, two new aryl-fluoroquinolone antimicrobial agents.
Smith BR; LeFrock JL; Donato JB; Joseph WS; Weber SJ
Antimicrob Agents Chemother; 1986 Feb; 29(2):355-8. PubMed ID: 3717937
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620 compared to that of other antimicrobial agents.
Hirschhorn L; Neu HC
Chemotherapy; 1987; 33(1):28-39. PubMed ID: 3549179
[TBL] [Abstract][Full Text] [Related]
5. Antibacterial activity of amifloxacin (WIN 49, 375), a new quinolone agent.
Neu HC; Labthavikul P
Diagn Microbiol Infect Dis; 1985 Nov; 3(6):469-78. PubMed ID: 4064609
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory and bactericidal activities of amifloxacin, a new quinolone carboxylic acid, compared with those of seven other antimicrobial agents.
Baltch AL; Sutphen NT; Smith RP; Conley PE
Clin Ther; 1984; 7(1):73-80. PubMed ID: 6440708
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.
Eliopoulos GM; Gardella A; Moellering RC
Antimicrob Agents Chemother; 1984 Mar; 25(3):331-5. PubMed ID: 6721464
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents.
Mandell W; Neu HC
Antimicrob Agents Chemother; 1986 May; 29(5):852-7. PubMed ID: 3729343
[TBL] [Abstract][Full Text] [Related]
9. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
[TBL] [Abstract][Full Text] [Related]
10. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
Bassey CM; Baltch AL; Smith RP
J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of CI-934 compared with ciprofloxacin, enoxacin, norfloxacin, and vancomycin.
Floyd-Reising SA; Kelley SG; Hindler JA; Young LS
Diagn Microbiol Infect Dis; 1987 Apr; 6(4):301-6. PubMed ID: 3472704
[TBL] [Abstract][Full Text] [Related]
12. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
King A; Phillips I
J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of ciprofloxacin (Bay o 9867).
Fass RJ
Antimicrob Agents Chemother; 1983 Oct; 24(4):568-74. PubMed ID: 6228192
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of the aryl-fluoroquinolones A-56619 and A-56620 and evaluation of disk susceptibility tests.
Barry AL; Jones RN; Thornsberry C; Ayers LW; Gavan TL; Gerlach EH
Eur J Clin Microbiol; 1986 Feb; 5(1):18-22. PubMed ID: 2938944
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of T-3761, a new fluoroquinolone.
Muratani T; Inoue M; Mitsuhashi S
Antimicrob Agents Chemother; 1992 Oct; 36(10):2293-303. PubMed ID: 1332594
[TBL] [Abstract][Full Text] [Related]
16. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C
Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177
[TBL] [Abstract][Full Text] [Related]
17. Amifloxacin activity against well-defined gentamicin-resistant, gram-negative bacteria.
John JF; Twitty JA
Antimicrob Agents Chemother; 1984 Nov; 26(5):781-4. PubMed ID: 6440481
[TBL] [Abstract][Full Text] [Related]
18. Antibacterial activity of a new tetracyclic quinolone, No. 5290, against norfloxacin- and ciprofloxacin-resistant strains of Staphylococcus aureus.
Kotera Y; Inoue Y; Ohashi M; Ito K; Tsukamoto G
Chem Pharm Bull (Tokyo); 1991 Oct; 39(10):2644-6. PubMed ID: 1666861
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro activity of three new quinolone antibiotics against recent clinical isolates.
Forsgren A
Scand J Infect Dis; 1985; 17(1):91-4. PubMed ID: 3158070
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent.
Eliopoulos GM; Klimm K; Rice LB; Ferraro MJ; Moellering RC
Antimicrob Agents Chemother; 1990 Jun; 34(6):1154-9. PubMed ID: 2393275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
